Best Series B Healthcare & Digital Health + Biotech & Life Sciences Investors 2026

Transforming disruptive European academic research into innovative therapeutics and diagnostics for severe diseases with high unmet medical needs. Operates as a venture builder, co-founding companies ex-nihilo from scientific discoveries and backing established venture-stage biotechs.

We invest in people solving difficult problems and building category-defining products in healthcare. We partner with visionary leaders at the intersection of medical technology and digital health to create transformative solutions that improve patient outcomes.

Invest in early-stage digital health companies that empower informed, connected health consumers to make confident decisions about their health. Focus on removing friction from healthcare, providing transparency, and enabling people to take control of their health journey through technology. Particular emphasis on solving structural problems in chronic disease management, mental health, reproductive health, aging in place, and specialty care navigation.

CVS Health Ventures invests in healthcare innovators that make care simpler, more accessible, and more affordable. The fund leverages CVS Health's national footprint — 9,000+ pharmacies, MinuteClinics, Aetna, and Oak Street Health — as a strategic distribution channel and operating partner for portfolio companies. Key focus areas: tech-enabled clinical workflows, disruptive care models, whole-person health, and consumer-centric experiences.

Fund and build next-generation life sciences companies solving important healthcare needs through cutting-edge breakthroughs in medicine and science. Partner closely with management teams to maximize returns across all portfolio companies through hands-on operational support, strategic guidance, and access to networks of experienced life science leaders.

Healthcare is one of the most compelling long-term investment opportunities globally, driven by aging demographics, rising healthcare spending, and continuous scientific innovation. We invest across the entire healthcare value chain to drive innovation and address unmet medical needs.

Breakthrough science merged with operational rigor creates transformational opportunities in life sciences. We identify emerging fields at the intersection of science and unmet medical need, then actively shape company formation working with scientific founders and expert advisors to design strategy from inception.

Venture capital can do more than fund companies—it can create them from the ground up. Newpath Partners specializes in building biotechnology companies in partnership with leading academic scientists, focusing on breakthrough biology platforms in gene editing, regenerative medicine, and transformational therapeutics that address the greatest unmet medical needs.

Breakthroughs at the convergence of technology, science, and humanity improve how we live, work, and experience the world. We invest in transformative technologies for human performance and wellbeing.

Science-driven venture capital focused on breakthrough healthcare innovations. Deep scientific rigor in diligence with mechanism-of-action understanding, proof-of-concept validation, and extensive KOL/clinician engagement. Backed by Zambon Group pharmaceutical expertise.

Complex health problems require multidisciplinary teams combining deep technical, financial, and domain expertise. We invest in breakthrough science and technology-enabled solutions across human and animal health.

Create first-in-category bioplatform companies through scientific innovation and systematic entrepreneurship. Combine institutional scale with pioneer creativity to build breakthrough life sciences companies.

Technology and biology are converging to create the next generation of transformative companies. The digitization of life sciences—driven by exponential growth in biological data and advances in AI/ML—is enabling a new class of platform companies that will dominate the industry. Tomorrow's biotech will be built by teams of three: a biologist, a chemist, and a computer scientist.

Atinum Investment identifies and invests in companies solving fundamental problems through technology innovation and market disruption. The firm specializes in growth-stage startups and paradigm-shifting companies across diverse sectors.

Passion and vision matter more than pedigree. We seek founders with grit, audacity, and a spark of rebellion—regardless of background. We invest early, before success is inevitable, and support founders from 0-to-1 through Series A.

The most enduring companies are created by founders willing to commercialize real science and scale real systems. We focus on hard tech at the intersection of computation and physical sciences—aerospace, biotech, energy, materials—where technical execution is the moat.

Data, cloud, and hardware advances will create unprecedented opportunities for great companies to be built. We invest in founders with big ideas and deep tech who are building infrastructure and value chains around data. Great people are the key to company success. We provide operational expertise, strategic guidance, and access to networks of mentors and international partners, particularly in China and Asia-Pacific.

The biggest companies of the century will be built solving the world's most pressing problems. We champion ambitious founders using technology to reshape civilization around climate, health, and inclusive capitalism.

Unearth, invest and grow startups into global leaders. iGlobe targets game-changing innovations at the frontier of deep tech — semiconductors, AI, quantum computing, and biotech — with a global orientation and a Singapore hub. Founded by Soo Boon Koh, Singapore's first female VC, the firm brings 25+ years of cross-border investing expertise and a top-quartile performance record.

Madrona invests in people and ideas for the long run — backing visionary founders building transformational technology companies, with deep focus on applied AI across domain-specific applications, AI infrastructure, developer tools, enterprise software, and AI-enabled biotech. The firm serves as an active, full-stack partner providing capital plus recruiting, business development, and customer introductions.

Mundi backs bold, purpose-driven founders building technology companies at the intersection of deep tech and critical global challenges. Core thesis: Europe has world-class talent and ecosystem but suffers from a scale-up funding gap at growth stages. Kembara fund (€750M) bridges this by providing Series B/C growth capital to European deep tech and climate champions.

Back extraordinary entrepreneurs throughout the company-building lifecycle from seed to IPO. Combine venture capital expertise with BCG management consulting to accelerate value creation. Support founders with capital, strategic guidance, and access to global networks.

We refuse to compromise between doing good and delivering strong financial and commercial returns. Portfolio companies gain access to TELUS's commercial networks, data-rich platforms, and deep expertise across agriculture, health, and connectivity giving them a unique edge as they scale.

Investing at the intersection of for-profit and for-good. Companies that make the world better AND deliver strong financial returns. The Villain Test ensures both impact and profit alignment.

Expand the AI ecosystem by backing technology visionaries solving complex problems to reshape our world. Focus on game changers and market makers in AI, robotics, biotech, autonomous vehicles, and applied AI. Leverage NVIDIA's unique position as GPU infrastructure leader to identify and support companies that will drive adoption of NVIDIA technology.

Technology can have a highly disruptive impact on society. We back founders on the forefront of innovation with clear vision towards positive change, leveraging domain expertise to ensure value creation. Founder-first approach with operational support.

As founder-operators, we see returns in relationships. We back ambitious founders with exceptional vision at the earliest stages with capital, mentorship, and network access.

Partner with visionary founders to turn bold ambitions into world-changing breakthroughs in life sciences, technology, healthtech, and crypto. Distinctive 'technical-risk-yes, regulatory-risk-no' filter ensures clear pathways to success.

Women founders represent an overlooked asset class that delivers superior returns. Women-founded companies earn 26% more for investors, yet receive only 2% of venture funding. We invest exclusively in women-founded companies, providing capital, network access, and operational support to drive transformative change.

GV backs innovative founders moving the world forward, operating on long time horizons and dealing in decades, not rounds. Since 2023, GV has accelerated its focus on AI-native companies across infrastructure, applications, healthcare, and developer tools — with approximately 80% of new European investments now in AI.

Invest in deep science and disruptive technology companies that solve fundamental human problems—inequality, health, climate adaptation. We back founders with vision, instinct, and drive to scale impact.

We democratize venture capital by providing individual accredited investors with professional-grade access to elite venture opportunities. We leverage our massive 850,000+ community network and 11,000+ investors to create unique value for founders, sourcing and diligencing deals alongside top-tier VCs (a16z, Sequoia, Khosla) without leading rounds. Our network is our competitive advantage—it compounds value for all stakeholders.

Breakthrough technologies that stretch the imagination — deep tech with the potential to create new product categories. We bring company-building skills and operating expertise to help founders find product-market fit.

K5 Global backs category-defining companies from inception to IPO. The firm leverages exceptional networks across media, entertainment, politics, finance, and technology to provide strategic value beyond capital. We believe the best companies are built by founders who can access world-class talent, capital, and strategic relationships.

As the world becomes more information-rich, most transformative new companies will leverage data science, machine learning, and advanced computing power. We back founders building breakthrough solutions at this intersection.

We back technically ambitious founders building tomorrow's most iconic companies in frontier sectors like AI, hardtech, robotics, healthcare, and fintech. We believe great companies come from founders willing to tackle complex problems that generalist funds avoid.

Back purposeful entrepreneurs building scalable technology solutions for significant Latin American problems, with emphasis on inclusion, climate innovation, and business productivity while generating positive impact and strong returns.

Back wild hearts with the wildest ideas from the very beginning. Invest in companies, not rounds — following exceptional founders from pre-seed through all subsequent stages. Focused on ANZ founders building globally ambitious companies across any sector.

Backs globally ambitious technology companies from pre-seed and seed through selected growth rounds using specialist EMEA sector teams and a platform model for capital, customers, talent, follow-on investors, and operational support.

NEA partners with ambitious founders at every stage of company building, from pre-seed through IPO. They invest at the intersection of technology and healthcare, believing the most transformational innovation occurs where deep domain expertise meets world-class technical founders. NEA serves as both capital provider and active operator.

Mubadala partners with world-class companies and institutions to drive transformational growth across strategic sectors and geographies. We believe in long-term value creation through patient capital, operational expertise, and global partnerships aligned with Abu Dhabi's economic diversification.

Backing the builders of the next layer of computing across AI infrastructure, defense, biotech, and American dynamism. Former 'Software is Eating the World' thesis evolved to 'AI is Eating Software'. Partners with technical founders building foundation models, cloud systems, and infrastructure for the AI era.

North Africa and Africa possess tremendous entrepreneurial talent. Strategic capital combined with operational expertise can unlock transformative solutions that reshape industries. We invest in founders solving region-critical problems.

Technology-based economic disruption of large markets through black swan investments. We seek founders with domain expertise and unreasonable conviction to build billion-dollar companies solving the world's largest problems.

Partner with exceptional founders to build generational companies that define the world's most critical industries. We provide not just capital but assemble teams of the highest caliber through our 5,000+ member builder community and deep operational expertise.

Backs DeepTech startups at the intersection of AI/ML, materials science, advanced manufacturing, biotechnology, optics, electronics, robotics, and blockchain — driving sustainable operational transformation across six thematics: transportation & logistics, energy & water, food & agriculture, fashion & beauty, precision medicine & aging, and retail & e-commerce. Requires commercial traction (min $1M revenue, 50%+ gross margins) and a minimum 10% ownership stake.

Back founders building iconic companies that transcend boundaries. We invest directly in their growth to make them unbreakable. Founded on principle that luck isn't made, it's engineered. Founders are our customer, not LPs. We always vote shares with founders and provide 1% non-dilutive founder development capital alongside every first check.

Back exceptional Kiwi founders building globally transformative companies, from day one to IPO. New Zealand founders represent a significantly undervalued asset class, and Icehouse provides capital plus an ecosystem of 3,000+ investors and deep operational support.

Emerson Collective invests in entrepreneurs and innovators driven by purpose, seeking consequential companies that deliver both generational impact and venture-scale returns. The firm targets sectors where biggest market opportunities meet meaningful impact levers: energy & environment, digital health, fintech, education, work, and media.

Data is the defensible moat in technology. We invest in companies that build proprietary data assets, analytics capabilities, or machine learning advantages to dominate their categories. Founded on 'information arbitrage' thesis - applying hedge fund quantitative discipline to early-stage venture.

AI is a milestone in data maturity progression, not a product category. Argonautic invests in founders building data-centric solutions across infrastructure (horizontal) and vertical markets. Multi-fund structure allows pre-seed to Series B deployment with unified thesis: recognizing verticals at different data adoption stages and deploying capital to those crossing inflection points into AI operationalization.

We invest in mission-driven companies that dare to tackle impossible challenges, striving to transform industries and create lasting societal impact. We seek founders with audacity to dream big, resilience to persevere, and potential to build forever companies that shape human history.

HOF Capital invests in relentlessly ambitious founders building world-changing technologies that accelerate abundance: sustained technological progress that expands access to opportunity, health, and economic prosperity. Its current public thesis emphasizes AI and agentic systems as amplifiers of discovery, engineering, and knowledge creation, alongside frontier infrastructure and applications that can shorten scientific and technological invention timelines.

We invest in technical breakthroughs that overcome the world's greatest challenges. We partner at inception with technically brilliant dreamers who see past impossible to inevitable. We evaluate scientific opportunities through both commercial potential and human impact lenses.

We partner with entrepreneurs from their early days through every stage of growth, focusing on innovative solutions in technology, healthcare, and financial services.

Equity of access and representation in venture capital delivers positive returns. Diverse and underrepresented (including LGBTQ+) leaders of high-growth companies deserve capital access. When these founders succeed, they influence ecosystems and open doors for historically excluded groups.

Startups positioned as transformation partners with Fortune 500 corporates create the most impactful solutions. We believe the next generation of market leaders will emerge through collaborative innovation between startups and incumbent enterprises, supported by global expertise and capital.

Back the world's most ambitious and transformative entrepreneurs capable of building world-defining companies over 20+ years. Invest in founders with independent thought and first-principles vision to solve humanity's biggest problems across all sectors and geographies.

Democratize access to venture capital by building large syndicates of non-traditional LPs. Invest across all stages, sectors, and geographies based on founder quality and market conviction, not category restrictions. Enable 2,000+ diverse co-investors to participate alongside marquee firms like Sequoia and Andreessen Horowitz while maintaining founder-friendly economics.

Invest in early-stage tech companies addressing world's largest market opportunities and solving humanity's biggest challenges. Leverage global distributed team to source, evaluate, and support transformational founders.